Denosumab Agents
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0027 alerts
Get alerted when Policy CC-0027 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity, prior-authorization, step-therapy, quantity-limit, and coding requirements for Prolia, Xgeva, and listed denosumab biosimilars for osteoporosis, glucocorticoid-induced osteoporosis, treatment-induced bone loss, metabolic bone disease, malignancy-related indications, giant cell tumor of bone, and hypercalcemia of malignancy.
The September 1, 2026 revision updated the step-therapy tables.
Ponlimsi was added to the Prolia biosimilar clinical criteria, step therapy, quantity limits, and applicable unclassified-drug coding.
Several denosumab biosimilars transitioned from unclassified-drug codes to specific Q-codes effective July 1, 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.